OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
12
Results
Show all
Save search
Copy query
Show results for
Unknown
(12)
Publication Date
Release Date
2020
(5)
2025
(2)
2024
(2)
2022
(2)
2021
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site.
Not available
S-EPMC7584883
|
biostudies-literature
Cite
Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.
Not available
S-EPMC11658795
|
biostudies-literature
Cite
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Not available
S-EPMC8274471
|
biostudies-literature
Cite
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Not available
S-EPMC11187765
|
biostudies-literature
Cite
Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19.
Not available
S-EPMC9109706
|
biostudies-literature
Cite
Management of Coronary Disease in Patients with Advanced Kidney Disease.
Not available
S-EPMC7274537
|
biostudies-literature
Cite
Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.
Not available
S-EPMC7255621
|
biostudies-literature
Cite
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
Not available
S-EPMC7263833
|
biostudies-literature
Cite
Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.
Not available
S-EPMC7261489
|
biostudies-literature
Cite
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
Not available
S-EPMC12492304
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets